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Abstract Bacterial infections are still one of the main
causes of patient morbidity and mortality worldwide.
Nowadays, many imaging techniques, like computed
tomography or magnetic resonance imaging, are used to
identify inflammatory processes, but, although they rec-
ognize anatomical modifications, they cannot easily dis-
tinguish bacterial infective foci from non bacterial
infections. In nuclear medicine, many efforts have been
made to develop specific radiopharmaceuticals to dis-
criminate infection from sterile inflammation. Several
compounds (antimicrobial peptides, leukocytes, cytokines,
antibiotics…) have been radiolabelled and tested in vitro
and in vivo, but none proved to be highly specific for
bacteria. Indeed factors, including the number and strain of
bacteria, the infection site, and the host condition may
affect the specificity of tested radiopharmaceuticals.
Ciprofloxacin has been proposed and intensively studied
because of its easy radiolabelling method, broad spectrum,
and low cost, but at the same time it presents some prob-
lems such as low stability or the risk of antibiotic resis-
tance. Therefore, in the present review studies with
ciprofloxacin and other radiolabelled antibiotics as possible
substitutes of ciprofloxacin are reported. Among them we
can distinguish different classes, such as cephalosporins,
fluoroquinolones, inhibitors of nucleic acid synthesis,
inhibitors of bacterial cell wall synthesis and inhibitors of
protein synthesis; then also others, like siderophores or
maltodextrin-based probes, have been discussed as bacte-
rial infection imaging agents. A systematic analysis was
performed to report the main characteristics and differ-
ences of each antibiotic to provide an overview about the
state of the art of imaging infection with radiolabelled
antibiotics.
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Introduction
Bacterial infections are still one of the main causes of
mortality and morbidity worldwide. This is also because of
the lack of specific agents to detect infective foci or to
discriminate infection from sterile inflammation. Diag-
nostic radiological imaging offers various techniques to
identify inflammatory processes, but they allow to detect
only anatomical changes of the infection and are not
always able to discriminate infections from normal post-
surgical changes in the early stages [1]. On the other hand,
nuclear medicine offers many radiopharmaceuticals that
can detect physiological and biochemical changes at the
early stages of infection. They include radiolabelled
antimicrobial peptides, antibiotics, leukocytes, but also
immunoglobulins and cytokines labelled with gamma- or
positron-emitting isotopes (18F, 99mTc, 111In, 67Ga etc.…)
[2–5]. In addition, the use of radiopharmaceuticals able to
detect T lymphocyte infiltration in autoimmune or
inflammatory bowel diseases (IBD) has been proposed as
an alternative approach [6]. Unfortunately none of these are
specific enough for bacteria thus allowing to discriminate
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infection from sterile inflammation, in spite of high sen-
sibility. This depends on the nature of the radiopharma-
ceutical, its biodistribution and binding properties but also
on the type of microorganism, the kind of infection, the
infection site and the host conditions. Another unsolved
issue is the minimum number of micro-organisms neces-
sary to perform a reliable diagnosis, which has already
been discussed [7]. In clinical nuclear medicine, among the
many 99mTc-labelled compounds, antibiotics looked the
most promising to image infection. They are divided in
several classes, based on their mechanism of action. The
first radiolabelled antibiotic, used as radiopharmaceutical,
was 99mTc-ciprofloxacin, that pioneered the use of radio-
pharmaceuticals for bacterial imaging. Nevertheless, it
appeared soon clear that the task of imaging bacteria is
very complex with many problems to be solved [7–9].
In this article, the use of radiolabelled ciprofloxacin is
reviewed together with other ‘‘infection-specific’’ radiola-
belled antibiotics, developed with the aim to discover tools
with better properties than 99mTc-ciprofloxacin. These
antibiotics are divided into several categories, according to
their mechanisms of action.
Bacteria, biofilm and antibiotic mechanisms
of action
Planktonic bacteria are free-living bacteria, which are
generally treatable with antibiotics but when they adhere to
a surface develop a biofilm. A commonly used definition of
a biofilm is a ‘‘microbially derived sessile community
characterized by cells that are irreversibly attached to a
substratum, interface or to each other, are embedded in a
matrix of extracellular polymeric substances that they have
produced, and exhibit an altered phenotype with respect to
growth rate and gene transcription’’ [10]. Biofilm embed-
ded bacteria represent a serious clinical problem in medi-
cine, because their infections are notoriously difficult to
treat due to extreme resistance to antibiotics.
Antibiotics are drugs of natural or synthetic origin that
have the capacity to kill (bactericidal drugs) or inhibit
(bacteriostatic drugs) the cell growth. Most bactericidal
antimicrobials are: cephalosporins, carbapenems, gly-
copeptides, fluoroquinolones, polymyxins that inhibit DNA
synthesis, RNA synthesis, cell wall synthesis, or bacterial
protein synthesis.
Fluoroquinolones (FQs) are bactericidal antibiotics
effective for both Gram-negative and Gram-positive bac-
teria and ciprofloxacin is the most widely used antimicro-
bial agent among FQs. The action of ciprofloxacin results
from inhibition of the enzymes topoisomerase II (DNA
gyrase, gyrA and B) and topoisomerase IV (grlA and B),
which are required for bacterial DNA replication,
transcription, repair, strand super coiling repair, and
recombination. Resistance to FQs in bacteria is mainly
mediated by alterations in DNA gyrase and topoisomerase
IV with specific amino acid substitutions in the ‘‘quino-
lone-resistance determining region’’ (QRDR) in gyrA and
B subunits of DNA gyrase and parC and parE subunits of
topoisomerase IV. Other common mechanisms are reduced
permeability/increased efflux of ciprofloxacin across bac-
terial membranes, and plasmids that protect cells from the
lethal effects of FQs [11, 12, 15].
Toxic effects of FQs on humans have been attributed to
their interactions with different receptor complexes, such
as blockade of the GABAa receptor complex within the
central nervous system, leading to excitotoxic type effects
and oxidative stress.
The cephalosporins are the largest family of b-lactam
antibiotics. They are bactericidal agents and have the same
mode of action as other beta-lactam antibiotics (such as
penicillin). Cephalosporins disrupt the synthesis of the
peptidoglycan layer of bacterial cell walls by binding to
penicillin binding proteins (PBPs), causing the walls to
break down and eventually the bacteria die. The three
fundamental mechanisms of antimicrobial resistance are:
enzymatic degradation of antibacterial drugs, changes in
PBPs, and changes in membrane permeability to antibi-
otics. The most important mechanism of resistance to
cephalosporins is destruction of beta-lactam rings by b-
lactamase enzymes. Mutational changes in original PBPs
or acquisition of different PBPs will lead to inability of the
antibiotic to bind to the PBPs and inhibit cell wall syn-
thesis. A change in the number or function of the general
diffusion porin channels can reduce the permeability.
Since antimicrobial compounds act on processes that are
unique to bacteria, it has been proposed that radiolabelled
antibiotic should be able to distinguish microbial from non
microbial inflammation, because of their specific binding to
the causative agents.
Ciprofloxacin
99mTc-ciprofloxacin, also known as Infecton, was the first
radiolabelled antibiotic tested in human to image infections
[8]. In preclinical studies many different animal models
have been used to prove ciprofloxacin specificity. In rats
99mTc-ciprofloxacin showed an excellent biodistribution
with renal clearance, and targeting experiments showed a
high sensitivity but low specificity. Ciprofloxacin was also
conjugated with propylamine and then labelled with 68Ga,
revealing to be a good bacteria-specific imaging agent in a
S. aureus infected rat model [16–18].
Different results were obtained when 99mTc-cipro-
floxacin was studied in mice and both high sensitivity and
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specificity for imaging infections were obtained
[14, 19–22].
Controversial results were obtained using other animal
models like rabbits, camelids, dogs or swines to evaluate
the ability of 99mTc-ciprofloxacin to localize the infectious
site, in severe acute pancreatitis, prosthetic joint infections
or other suspected infections [23–26].
In clinical studies, it was more difficult to study the
pharmacokinetics of ciprofloxacin in organs and tissues,
particularly in the gastrointestinal tract, lungs and soft
tissues.
Positron Emission Tomography (PET) could be a tech-
nique that allows a direct quantification of the antibiotic,
when labelled with positron-emitting isotopes like 18F.
Indeed, two studies performed by Brunner et al. and Langer
et al. [13, 27], using PET with 18F-ciprofloxacin, showed
opposite results in healthy volunteers and patients with
suspected infections, respectively. In particular Langer and
colleagues concluded that 18F-ciprofloxacin is not a suit-
able and specific radiopharmaceutical for imaging
infections.
Many other studies in patients have been performed
using 99mTc-labelled ciprofloxacin. Most of them had
concordant results about the labelling procedure using the
kit formulated at St. Bartholomew’s Hospital in London
[28] and about the metabolism of the radiopharmaceutical,
which was prevalently renal, with low level of hepatic
uptake and no bone marrow, bone and gastrointestinal
uptake. However, final results showed a high variability in
terms of sensibility and specificity. These controversial and
variable data may depend on the type and site of infections,
strain of micro-organisms, presence of antibiotic therapy,
lack of standardized imaging parameters and interpretation
criteria, but also on the type of imaging modality (SPECT
or planar scintigraphy) [29, 30]. Some authors have con-
sidered Infecton as a good bacterial infection imaging
agent, particularly when SPECT images are acquired for
the diagnosis of pulmonary or extrapulmonary tuberculo-
sis, fever or unknown origin (FUO), osteomyelitis, hip or
knee prosthesis, active spinal infections, abdominal or
gastrointestinal and orthopaedic infections, despite of
conflicting results based on the type of infection. More-
over, it allows to evaluate the presence of infection in
immune-suppressed patients, when white blood cell
(WBC) imaging was uncertain or to monitor and optimize
the antimicrobial treatment. However, in addition to image
analysis, a microbiological culture was often useful to
confirm the presence and nature of the infection
[8, 28, 31–44]. Other authors have considered 99mTc-
ciprofloxacin as a potential imaging agent only for the
diagnosis of orthopaedic infections, vertebral infections,
osteoarticular tuberculosis and diabetic foot infections, in
comparison to 99mTc-WBC or immunoscintigraphy,
showing excellent diagnostic accuracy [45–50]. By con-
trast, other studies, by Dumarey et al., De Winter et al.,
Sarda et al., Pucar et al., Appelboom et al. and Gemmel
et al. [51–56], reported a low specificity but high sensitivity
for Infecton imaging. These studies were performed in
patients with different kind of infections and images were
acquired and analyzed with different methods, but all
concluded that 99mTc-ciprofloxacin is unable to discrimi-
nate bacterial infection from sterile inflammation.
Finally, Zhang et al. [57, 58] performed a study with
ciprofloxacin dithiocarbamate labelled with [99mTcN]2?
intermediate or [99mTc(CO)3(H2O)3]
? intermediate. These
radiopharmaceuticals were tested in S. aureus infected
mice to evaluate their biodistribution and their ability to
distinguish septic and aseptic inflammation in comparison
to 99mTc-ciprofloxacin. Experimental data showed that
both new radiopharmaceuticals had a better target-to-non
target (T/NT) ratio than 99mTc-ciprofloxacin and they could
be considered potential infection imaging agents.
Fluoroquinolones
The quinolones can be differentiated in several generations,
which differ for broad-spectrum activity and pharmacoki-
netic properties like a rapid and complete absorption from
gastrointestinal tract or oral administration [59, 60].
For example pefloxacin is a fluoroquinolone antibacte-
rial agent, which has been investigated as a potential sub-
stitute for ciprofloxacin in the detection of bacterial
infections. It was labelled with 99mTc, tested in mice
infected with E. coli or injected with turpentine oil as
sterile inflammation. Experimental data showed a main
excretion through liver and intestine and a high retention in
infectious foci than aseptic foci after 24 h from injection
because of its specific binding to gyrase, confirmed by the
T/NT ratio equal to 5.6 at 24 h post injection. Moreover
pefloxacin had a rapid clearance, no accumulation in non-
target organs, no toxicity, low cost and a simple prepara-
tion, that makes it a good potential imaging agent [61].
The second generation of fluoroquinolones includes
many compounds, more or less specific for bacterial
infections. Amongst the most specific agents there are
lomefloxacin and ofloxacin that were always studied in
comparison to ciprofloxacin. The radiolabelling procedure
with 99mTc is easy, without any purification in comparison
to ciprofloxacin and they have been tested in S. aureus
infected rats compared to normal rats as control. The
biodistribution studies, obtained by ex vivo c-counting,
revealed renal excretion and low uptake in the liver, that
indicates few hydrolyzed products of 99mTc for both
antibiotics. T/NT ratio for lomefloxacin was higher than for
ofloxacin, 6.5 ± 0.5 and 4.3 ± 0.6 respectively,
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suggesting that lomefloxacin might be a better imaging
agent than ofloxacin [62]. The low specificity of ofloxacin
has been confirmed in another study performed by Erfani
et al. They labelled the antibiotic with 99mTc and investi-
gated the biodistribution in S. aureus infected mice. Also in
this case authors found a renal and liver clearance and a T/
NT ratio equal to 2.02 ± 0.12 at 4 h after injection, a sign
of poor specificity [63].
Two other poorly specific antibiotics are enrofloxacin
and norfloxacin. The former was studied in comparison to
ciprofloxacin by Siaens et al. It was radiolabelled with
99mTc and injected in S. aureus treated rats. In this study
the control rats were injected with turpentine oil, heat
killed S. aureus or C. albicans. Results showed high renal
uptake and no significant differences in the level of accu-
mulation in the various inflamed muscles, indicating poor
capacity to recognize infection from sterile inflammation
[64]. Recently, 99mTc-enrofloxacin was also studied by
Shahzad et al. [65], obtaining more or less the same results
as previously published by others. Indeed, the radiolabelled
compound always showed the same biodistribution in non
target organs and no high uptake in the infected muscle
versus control.
The other non specific antibiotic, norfloxacin, was also
labelled with 99mTc and its biodistribution evaluated in rats
infected with 107–108 CFU of S. aureus, heat killed S.
aureus and turpentine oil. 99mTc-norfloxacin has an
excretion through the urinary system and the uptake in
infected or non-infected muscles is not statistically differ-
ent. Based on these data, it was concluded that norfloxacin
cannot discriminate bacterial infection from sterile
inflammation [66]. However, controversial results about
norfloxacin were recently reported by Sazonova et al. [67]
in rats where infection was induced with 109 CFU of S.
aureus. Turpentine oil was used as control. Their results
showed a mild uptake in the infected muscle as compared
to inflamed one. The T/NT ratios were 2.87 ± 0.80 and
1 ± 0.14, respectively, for infected and inflamed muscle,
confirming that this radiopharmaceutical requires further
studies to improve its specificity. Another study, performed
by Zhang et al. [68], tested norfloxacin dithiocarbamate as
a potential imaging agent. It was labelled with 99mTc and
the biodistribution was studied in S. aureus infected mice,
while sterile inflammation was induced using turpentine
oil. Experimental data revealed a main hepato-biliary
clearance and the T/NT ratios were 3.46 and 1.23 at 3 h
post-injection, respectively for bacterial infection and
sterile inflammation.
With third-generation FQs several properties were
improved through modifications of the quinolone nucleus,
such as anti-microbial activity and pharmacokinetics [69].
An antibiotic of this category, that could be a substitute
of ciprofloxacin, is sparfloxacin. It was labelled with 99mTc
and then biodistribution was studied in rats where infection
was induced using 105-106 CFU of S. aureus. Biodistri-
bution studies showed a rapid clearance through the urinary
system and a high accumulation in the infection site, more
than ciprofloxacin. As early as 2 h post-injection, the T/NT
ratio was 5.10 ± 0.4 for sparfloxacin and 3.60 ± 0.4 for
ciprofloxacin [9]. It is also remarkable that in this study
very few CFU of S. aureus were used (only 105–106) as
compared to the majority of published studies ranging from
107 to 1010 CFU.
Levofloxacin is another third-generation fluoro-
quinolone. Shahzad et al. [70] labelled this antibiotic with
99mTc using a freeze-dried kit. Biodistribution was studied
in rabbit, infected with two different strains of bacteria
(3 9 108 CFU of E. coli and P. aeruginosa). Results
showed kidneys as the main excretion route and T/NT
ratios were 8.09 and 1.3 at 1 h post-injection, respectively
in P. aeruginosa and E. coli infected muscles showing high
variability depending on the kind of bacteria. Therefore
99mTc-levofloxacin could be a promising imaging agent for
lung, sinus bone and skin infections, but it also needs other
studies.
A fluoroquinolone derivative that is able to distinguish
between septic and aseptic inflammation is rufloxacin. It
was always labelled with 99mTc and the biological distri-
bution was evaluated in Albino mice after induction of
infection with live E. coli and inflammation with turpentine
oil or heat killed E. coli. Experimental data revealed an
excretion through kidneys and urine and the uptake in the
infected muscles were higher than heat-killed bacteria and
turpentine oil inflamed muscle. The T/NT ratio was also
higher compared to ciprofloxacin at all time points
(8.5 ± 0.1 vs 3.6 ± 0.4 3 h post injection), demonstrating
that rufloxacin could be a good infection imaging agent
[71].
Another third generation fluoroquinolone is fleroxacin
that it was studied as a PET radiopharmaceutical by Fis-
chman et al. [72]. It was labelled with 18F and its phar-
macokinetics was evaluated in healthy and E. coli infected
rabbits, mice and rats. Biodistribution showed a main
excretion through the intestinal tract, then liver and kidneys
and no accumulation in the brain, especially in rats and
mice. Unfortunately the accumulation in healthy and
infected muscle of all animals was similar and 18F-flerox-
acin was considered a poor PET imaging agent for bacteria.
Compared to previous generation, the fourth generation
of FQs has the advantage to be resistant to spontaneous
mutation, reducing the risk of antibiotic resistance. Their
mechanism of action is the inhibition of DNA gyrase and
topoisomerase IV, enhancing the Gram-positive spectrum,
especially for ocular infections [73].
Sitafloxacin belongs to this generation. It was labelled
with 99mTc and biodistribution studies and scintigraphic
232 Clin Transl Imaging (2016) 4:229–252
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images were evaluated, respectively in rats and rabbits,
where infection was induced with 2 9 108 S. aureus and
inflammation induced with turpentine oil. Biodistribution
confirmed the renal excretion also for this class of antibi-
otics with a high accumulation in infected muscles con-
firmed by in vivo images and T/NT ratio equal to
23.13 ± 0.1 at 2 h post injection. This T/NT ratio was the
highest obtained with a radiolabelled antibiotic suggesting
sitafloxacin as the best imaging agent for imaging infec-
tions caused by S. aureus [74]. It would be important to
determine whether it can image also other strains of bac-
teria and whether the accumulation lasts over time.
Due to initial enthusiasm, sitafloxacin was chemically
modified to sitafloxacin-dithiocarbamate, which is more
stable, and then labelled with 99mTc via a [99mTcN]2? core.
Biodistribution studies and whole body images were per-
formed in rats and rabbits, infected with S. aureus and
turpentine oil and heat killed bacteria as controls. Experi-
mental data showed a clearance through the kidneys and
confirmed the high uptake in the infected muscle with
living bacteria. The T/NT ratio was 7.40 ± 1 after 2 h from
injection in the infectious foci, as compared to 1 ± 1 in the
inflamed area, confirming this radiopharmaceutical as a
very promising infection imaging agent [75].
99mTc-moxifloxacin could be considered another
potential agent. It was studied in rats and rabbits after the
induction of a septic inflammation with E. coli in the thigh
muscle. On images it was possible to notice the infected
site in a clear way, with a specific accumulation six times
higher than in normal tissues [76].
Another antibiotic of this generation, specific for S.
pneumoniae infection, is gemifloxacin. After labelling with
99mTc, it was tested in infected, inflamed and normal rats.
Results showed an early uptake in the liver, followed by a
renal clearance; the T/NT ratio between infected and nor-
mal muscle was maximum at 90 min and then decreased
slightly [77]. Recently, another study, performed by
Shahzad et al. [78], confirmed the specificity of 99mTc-
gemifloxacin to localize respiratory tract infections. The
radiopharmaceutical was studied in rabbits infected with
three different strains of bacteria (3 9 108 CFU), including
K. pneumoniae, S. typhi and P. aeruginosa. The maximum
T/NT ratios were 8, 8.87 and 16.5 at 4 h post-injection,
respectively for the three kinds of bacteria, confirming that
99mTc-gemifloxacin could be used as a bacterial imaging
agent for lung infections.
Finally, another fluoroquinolone derivative has been
proposed as ciprofloxacin’s substitute by Moustapha et al.
[79]. 99mTc-sarafloxacin was studied in vitro and in S.
aureus infected mice, while as turpentine oil and heat
killed bacteria were used to induce the aseptic inflamma-
tion. Experimental data revealed both renal and hepatic
excretion with a low uptake in the infectious foci as
compared to other quinolones of fourth generation. T/NT
ratio in infected mice was 4.2 ± 0.1 at 2 h post injection,
versus 3.4 and 3.3 for turpentine oil and heat killed
bacteria.
Cephalosporins
Cephalosporins have also been radiolabelled for bacteria
imaging in vivo. In 2013 El-Tawoosy et al. studied the best
labelling condition of cephazolin with 99mTc and its bio-
logical distribution in murine model, infected with S.
aureus (107–108 CFU) and turpentine oil as control.
Results showed a good preparation and labelling of the
product, a rapid distribution in mice with excretion through
kidneys and intestine by 2 h, and a infected/inflamed
muscle ratio (T/NT) equal to 4.60 ± 0.21 at 2 h. However,
since the highest ratio was 8.57 ± 0.40 at 30 min, cepha-
zolin is able to distinguish well the early stages of infection
from sterile inflammation [80].
The second generation of cephalosporins has a spectrum
of activity like the first generation antibiotics, but more
active against Gram-negative bacteria, and includes
antibiotics as cefuroxime axetil, whose bactericidal activity
is the inhibition of cell wall synthesis through the binding
to specific proteins. Its potential use as a radiopharma-
ceutical has been tested in rats with sterile and septic
inflammation, caused by 108 CFU of S. aureus, in the Yurt
Lambrecht’s study. Results showed a rapid clearance by
liver and kidney and a better retention in infectious areas
than sterile inflamed areas because of its specific binding to
gyrase enzymes. However, authors reported a low T/NT
ratio at 30 min (1.6), with a slight increase at 4 h (2.5).
This suggests that 99mTc-cefuroxime acetil could be a
promising infection imaging agent, but more studies are
needed to confirm this hypothesis [81]. Cefuroxime is
another second-generation cephalosporin antibiotic that
was labelled and tested in a study performed by Chat-
topadhyay et al. [82]. After labelling with 99mTc, the
compound was injected in rats infected with 106–108 CFU
of E. coli bacteria in the left thigh. Experimental data
showed a renal and hepatic excretion and a poor accumu-
lation in the infection site, confirmed by the T/NT ratio
(1.8) at 3 h from the injection. Therefore 99mTc-cefuroxime
is not entirely able to distinguish bacterial infections.
Third-generation cephalosporins are broad-spectrum
antimicrobial agents used in many clinical situations.
Among them, ceftizoxime has the best Gram-positive
coverage [83]. Gomes Barreto et al. labelled it with 99mTc
for imaging of E. coli infection in rats’ muscle compared to
controls and animals bearing a sterile zymosan induced
abscess. Experimental data underlined a maximum uptake
in kidneys and a significant uptake in the septic muscle
Clin Transl Imaging (2016) 4:229–252 233
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rather than in the sterile one. The uptake persisted up to
6 h, as confirmed by a T/NT ratio of 3.24 ± 1 in the
infection site, (1.65 ± 0.23 in controls). On the basis of
obtained data, 99mTc-ceftizoxime showed a moderate
specificity that lead researchers to investigate its use in
other models [84].
Costa et al. tested this radiolabelled antibiotic for the
diagnosis of deep sternal wound infection. They used
twenty rats divided into four groups, two controls and two
with sternotomy and infection with S. aureus. Scintigraphic
images revealed a higher levels of radioactivity, expressed
as number of counts, in the region of interest of infected
rats (12,258.2 ± 1729 counts/10 min) than control coun-
terparts (4920.6 ± 562.9) in different time points after
injection. This result confirmed that 99mTc-ceftizoxime is a
potential antimicrobial agent, which detects infection post
sternotomy [85].
Also Teixeira et al. [86] used 99mTc-ceftizoxime for the
diagnosis of suspected infections in titanium implants in rat
model. Control rats received a sterile implant, while
experimental group received an implant infected with 109
CFU of S. aureus. Scintigraphic images showed higher
uptake in infectious area in rats than in controls, expressed
as the difference between groups, at 6.5 h post-injection.
Despite these promising results in localizing infected
implants, further studies are required to improve sensitivity
and specificity of 99mTc-ceftizoxime.
Cefotaxime has a similar structure of ceftizoxime and
was studied by Mirshojaei et al. [87] as a potential
infection-imaging agent. After labelling with 99mTc, the
biological distribution was performed in mice, infected
with 108 CFU of S. aureus bacteria in the thigh muscle.
Results showed a renal clearance, low hepato-biliary
excretion and a poor accumulation in the infectious site
with the maximum T/NT ratio at 1 h (2.89 ± 0.58).
Although a more rapid metabolic route, when compared
to 99mTc-ciprofloxacin, 99mTc-cefotaxime requires more
studies to demonstrate its specificity. Ilem-Ozdemir and
coll. [88] labelled with 99mTc the cefotaxime sodium.
Then, they evaluated its biodistribution in rats, infected
with 4 9 1010 CFU of E. coli or turpentine oil as control.
Results showed a main renal excretion of radiopharma-
ceutical and a very poorly uptake in the infectious foci.
Indeed the T/NT ratios were 3.77 ± 2.38 and 3.30 ± 0.94
at 1 h post injection.
Another third-generation cephalosporin, tested by vari-
ous authors, is ceftriaxone. Also for this antibiotic, similar
results were obtained and 99mTc-ceftriaxone could be able
to distinguish sterile and septic inflammation. The first
study, performed by Mostafa et al. in 2010, describes the
labelling of ceftriaxone with 99mTc and its biodistribution
in a mouse model, infected with alive E. coli, heat killed
bacteria and turpentine oil as controls. In this study the
ability to differentiate between bacterial infection and
sterile inflammation was demonstrated in vitro and con-
firmed in vivo. In mice, it showed renal excretion and a
good retention at the infectious site because of its specific
binding to bacteria. T/NT ratio for the living bacteria was
5.67 ± 0.6 at 4 h post injection as compared to the tur-
pentine oil and heat killed E. coli ratios that were less of 2
[89]. The second study about ceftriaxone was published by
Kaul et al. in 2012. The main purpose of the study was to
assess the efficacy of 99mTc-ceftriaxone in vitro through
bacterial binding assay with living and heat killed S. Aur-
eus, but also in vivo in murine and rabbit models and in
humans. Results confirmed the ability of the labelled
antibiotic to discriminate between inflammation and
infection: in fact scintigraphic images in rabbit showed a
higher uptake in the infectious site than in the inflamed
muscle at 4 and 24 h, and also the T/NT ratio in mice with
septic lesion was 4.5 at 24 h as compared to sterile
inflammation that showed 1.4 at 24 h. Clinical studies
demonstrated that the radiolabelled antibiotic localizes
acute bacterial infections, especially in bacterial
osteomyelitis and could be used for diagnosis of other
orthopaedic infections too [90]. A third study with 99mTc-
ceftriaxone was performed by Fazli et al. [91], but it did not
confirm the good specificity previously published by oth-
ers. They tested it in a murine model, comparing an
infection with living S. aureus, to a sterile inflammation
with heat killed bacteria or turpentine oil. Experimental
data showed a renal excretion and a poorly specific accu-
mulation in the infected muscle in comparison to inflamed
and normal muscles. The T/NT ratio in infected muscles
was 3.39 ± 0.6 at 3 h post injection, while the T/NT in
muscles with turpentine oil or with heat killed bacteria
were, respectively, 3.12 ± 0.35 and 2.48 ± 0.45 always at
3 h post injection with no statistically significant difference
between the 3 groups [91]. Finally, Sohaib et al. [92]
confirmed the ability of this radiopharmaceutical to dis-
criminate the infection from inflammation. 99mTc-ceftri-
axone was tested in rats, infected with 108 CFU of S.
aureus or E. coli, whereas turpentine oil was used in
control rats. Biodistribution studies revealed a main renal
excretion, followed by liver and intestine, and high accu-
mulation in the infectious area in animals injected with
E. coli rather than S. aureus or turpentine oil. These data
were confirmed by T/NT ratios equal to 12.66 ± 1.44,
2.35 ± 0.21 and 1.4 ± 0.01, respectively, suggesting that
99mTc-ceftriaxone could be used as a microbial imaging
agent only for E. coli.
Another third-generation antibiotic, studied by Mirsho-
jaei et al. is ceftazimide. It was labelled with 99mTc and its
biodistribution was tested in normal and S. aureus infected
mice. Data showed a similar uptake of radiopharmaceutical
in non target organs (liver, spleen, heart and lung) between
234 Clin Transl Imaging (2016) 4:229–252
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control and infected animals with lower hepato-biliary
excretion when compared to 99mTc-ciprofloxacin; about
accumulation in the infected and control muscle, the ratio
was 1.4 ± 0.2 at 1 h post injection and 1.1 ± 0.1 at 4 h.
Therefore, ceftazimide did not show the same specificity of
ceftizoxime and ceftriaxone, as bacterial imaging agent
[93].
Cefoperazone is another third-generation cephalospor-
ine, studied to evaluate the best radiolabelling conditions
with 99mTc and its biological distribution in a rat model of
S. aureus bacterial infection. In vivo results, expressed as
%ID/g, showed a renal clearance and a 4.5-fold higher
uptake in the infected tissue than control, with a maximum
T/NT ratio at 45 min post injection of 4.66 ± 0.53: then
this value decreased with time (2.9 ± 0.75 at 5 h), proba-
bly because of bacterial killing by radiopharmaceutical or
clearance from circulation. These data make cefoperazone
a promising agent for detection of infectious foci, even if it
needs further investigations [94].
Belonging to fourth-generation of cephalosporins is
cefepime, whose biological efficacy and specificity were
compared to gatifloxacin, a fluoroquinolone derivative. The
two radiopharmaceuticals were labelled with 99mTc and
tested in rats infected with living E. coli, heat killed bac-
teria and turpentine oil. After successful in vitro quality
controls and bacterial binding assay, biodistribution studies
were performed and results demonstrated a liver uptake for
both radiopharmaceuticals that decreases with time. The
uptake in the infectious foci was better for 99mTc-cefepime
than for 99mTc-gatifloxacin (T/NT ratio was 8.4 ± 0.1 at
3 h post injection for 99mTc-cefepime and 4.5 ± 0.3 for
99mTc-gatifloxacin in infected muscles with living bacte-
ria): Thus, cefepime was able to distinguish between sterile
and septic inflammation better than all other antibiotics
[95].
Inhibitors of nucleic acid synthesis
The inhibition of nucleic acid synthesis occurs through the
binding of the antimicrobial to DNA-dependent RNA
polymerase, blocking the initiation of RNA synthesis, or to
DNA gyrase, inhibiting DNA synthesis [96].
Rifampicin is particularly indicated for the treatment of
tuberculosis, and recently an imaging agent for PET use
has been developed for latent tuberculosis detection,
labelled with 11C. 11C-rifampicin was tested in preclinical
studies to evaluate whether there is sufficient drug in the
infected site because the radiopharmaceutical is able to
accumulate in a hypoxic environment like the tuberculotic
granuloma [97].
However, in animals rifampicin was studied for detec-
tion of methicillin-resistant S. aureus (MRSA) infections in
both rats and rabbits. Turpentine oil induced inflammation
is always the method of choice for control. After labelling
with 99mTc, biodistribution revealed a long renal clearance,
and a high accumulation in the infectious foci, confirmed
by in vivo calculated T/NT ratio (7.34 ± 0.74 at 90 min
post injection) [98].
Another antibiotic that indirectly acts on nucleic acid, in
particular DNA, is nitrofurantoin: it is often used for uri-
nary tract infections because many uropathogens have not
yet developed resistance to it. Its mechanism of action is
still unclear, but it seems that bacterial nitroreductase
enzymes transform the antibiotic into more reactive inter-
mediates that lead to single-strand breaks in DNA through
interaction with bacterial ribosomal proteins [99]. 99mTc-
nitrofurantoin was investigated in E. coli infected rats and
rabbits. In vivo distribution showed an early uptake in the
liver and stomach, while the accumulation in infectious
foci rapidly increased in a time-dependent manner as
compared to controls, with a peak at 90 min p.i., with a T/
NT ratio equal to 4.83 ± 1.13 [100].
Inhibitors of bacterial cell wall synthesis
This category of antibiotics may inhibit many steps of cell
wall synthesis, above all the inhibition of peptidoglycan
synthesis, because cell wall is essential for survival of
bacteria; but also the membrane transport mechanisms,
resulting in osmotic lysis [101].
An example of these antibiotics is the well-known
amoxicillin, a penicillin derivative that acts by inhibiting
the third and last stage of bacterial cell wall synthesis. It is
particularly active on S. pneumoniae [102]. Amoxicillin
was recently labelled with 99mTc and its biological distri-
bution was studied in S. pneumoniae infected rabbits.
Results were promising but not as good as for other radi-
olabeled antibiotics and maximum accumulation in the
infection was recorded 2 h post-injection [103].
By contrast, alafosfalin is a dipeptide phosphonic acid,
active against both Gram-positive and Gram-negative
bacteria. It inhibits the early stage of peptidoglycan syn-
thesis because it mimics the terminal dipeptide moiety (D-
Ala-D-Ala), inhibiting the enzyme D-Ala-D-Ala syn-
thetase, or inhibits the enzyme alanine racemase for its
affinity to racemase cofactors [104]. When labelled with
99mTc it showed rapid renal excretion in rats, infected with
108 CFU of S. Aureus. Interestingly, Tsopelas et al. com-
pared 99mTc-alafosfalin with 99mTc-DTPA and 99mTc-la-
belled-leukocytes and showed that the T/NT ratio at 4 h p.i.
for 99mTc-alafosfalin was higher than for 99mTc-DTPA
(4.32 ± 0.26 vs 1.93 ± 0.15) but lower than for 99mTc-
WBC. These results were also confirmed by scintigraphic
images and histological studies, suggesting that 99mTc-
Clin Transl Imaging (2016) 4:229–252 235
123
alafosfalin complex is not as specific as WBC for detecting
bone infections, particularly in case of high probability of
infection [105].
The bacterial cell wall is mainly composed by pepti-
doglycan, which is formed from alternating units of N-
acetylglucosamine and N-acetylmuramic acid. The intro-
duction of positron emitter isotope into N-acetylglu-
cosamine structure could be a solution for the detection
bacteria using PET imaging [5]. Thus, Martı`nez et al.
described a new labelling method of 2-deoxy-2-[18F]fluo-
roacetamido-D-glucopyranose ([18F]FAG) trough micro-
wave irradiation, and demonstrated its ability to
discriminate, in vivo, a bacterial infection from a sterile
inflammation. They used a mouse model, infected with 107
CFU of E. coli or a sterile inflammation with turpentine oil
for biodistribution studies and rats for acquiring PET
images, followed by histology and immunostaining of
relevant tissues. Images showed a high accumulation of
[18F]FAG in the infectious foci, similar to [18F]FDG, but
there was no uptake of [18F]FAG in the sterile inflamma-
tory lesion as compared to [18F]FDG. Haematoxylin-eosin
and immunostaining using anti-E. coli antibodies con-
firmed the presence of bacteria in the infected tissue and an
infiltration of granulocytes and macrophages, while in
turpentine oil-induced inflammation, neutrophils and
macrophages prevailed, demonstrating that [18F]FAG is
able to distinguish bacterial infections from inflammation
in contrast to [18F]FDG [106].
Another antibiotic that inhibits the bacterial cell wall
synthesis is vancomycin. Because of its big size and
complex structure, vancomycin does not enter the mem-
brane of Gram-negative bacteria, but binds to peptidogly-
can precursors, preventing their lipid carrier-mediated
transfer through the membrane [107]. Vancomycin was
also labelled with 99mTc and in vitro studies (binding assay
to bacteria and stability test) were performed as well as
in vivo studies (biodistribution and targeting in S. aureus
infected rats). Results showed both liver and kidneys
metabolism and a high uptake of in the infected muscle
with a T/NT ratio equal to 5 at 60 min post injection [108].
Inhibitors of protein synthesis
Protein synthesis inhibitors include various classes of
antibiotics, each of which blocks the process in a different
way, in particular at the ribosomal level [109].
An example is kanamycin, a bactericidal agent of
aminoglycoside family, used for the treatment of infections
when penicillin cannot be used such as bone, skin or
abdominal infections. Its mechanism of action is the pre-
mature chain termination and RNA codon misreading by
the interference with 30S ribosome. It was labelled with
99mTc by a simple and easy procedure and then tested in
rats for in vivo distribution and in rabbits for scintigraphy,
in which infection was induced with 2 9 108 CFU of S.
aureus. The tissue distribution showed a renal elimination
and a high uptake in the infectious foci as compared to
normal muscle used as control, with a T/NT ratio greater
than 2 up to 24 h from injection [110].
Belonging to these inhibitors there are two other
antibiotics, doxycycline hyclate (DOX) and erythromycin.
DOX is an antibacterial tetracycline derivative, with a wide
range of activity against Gram-negative and Gram-positive
bacteria; it binds to 30S subunit of ribosome, preventing
the binding between aminoacyl tRNA and the acceptor site
on mRNA. 99mTc-DOX was tested in vivo in rats, infected
with 4 9 1010 CFU of E. Coli. The excretion was mainly
through kidneys, but also through stomach because of high
intestinal activity despite liver uptake was low. The highest
T/NT ratio was 2.62 ± 0.88 after 5 h from the radiotracer
injection. According to previous studies, the radiophar-
maceutical had a high uptake both in the infected and
inflamed thigh muscle, indicating that 99mTc-DOX cannot
differentiate bacterial infection from sterile inflammation
[111].
Erythromycin is a bacteriostatic agent of macrolides
family and it inhibits the transpeptidation or translocation
because of a missed binding of tRNA to the specific site by
the binding to 50S ribosomal subunit [96]. Biodistribution
studies were performed in mice infected with 105–106 CFU
of S. aureus or turpentine oil as control. Experimental data
showed a main elimination through renal and urinary
pathway at 4 h from injection of radiotracer and a liver
uptake that decreased with time. The T/NT ratio of 99mTc-
erythromycin in infected muscle was greater than cipro-
floxacin (5 ± 0.6 vs 3.8 ± 0.8) at 30 min post injection,
but at the same time values of T/NT ratio were comparable
in infected and inflamed mice, respectively 5 ± 0.6 and
4.8 ± 0.4. Thus, 99mTc-erythromycin complex accumu-
lates in infected muscles, but it cannot distinguish between
septic and aseptic inflammation [112]. Another not very
specific antibiotic of this category is vibramycin. It was
labelled with 99mTc and then tested in a rats. The infection
was induced with 2 9 108 CFU of live S. aureus, while for
the inflammation heat-killed bacteria or turpentine oil were
used. Biodistribution revealed a main hepato-biliary
excretion and not high accumulation of radiopharmaceu-
tical in the infectious site compared to controls, confirmed
by similar values of T/NT ratios (2.64, 2.15 and 1.80,
respectively in live bacteria, heat killed bacteria and tur-
pentine oil). Therefore these results show that 99mTc-vi-
bramycin cannot be considered a specific infection imaging
agent [113].
By contrast, azithromycin, clarithromycin and clin-
damycin are three inhibitors of protein synthesis, which
236 Clin Transl Imaging (2016) 4:229–252
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could be novel potential bacterial imaging agents. Azi-
thromycin, like erythromycin, belongs to macrolides, but
differs for the structure and the activity level against Gram-
positive and Gram-negative bacteria [114]. It was also
labelled with 99mTc and biodistribution studies were per-
formed in mice, where infection was induced with S.
aureus in the thigh muscle. Inflammation was induced with
direct injection of turpentine oil and heat killed bacteria.
The quantitative evaluation, expressed as the percentage of
injected dose per organ, showed an excretion through
kidneys and urine, and high accumulation in infectious
muscle than controls, confirmed by the T/NT ratio: the
maximum peak was 6.20 ± 0.12 at 2 h post-injection, but
at all time intervals values were significantly higher than
sterile inflamed muscles [115].
Clarithromycin is a derivative of erythromycin and it was
labelled with 99mTc. Mice infected with 108 CFU of S. aureus
were used as a model, while turpentine oil and heat killed
bacteria were used as control. Biodistribution showed an
excretion of radiopharmaceutical mainly through the urinary
pathway and a high uptake in the site of infection was
observed as compared to controls. T/NT ratios were
7.33 ± 0.13 at 2 h for the infection model, while 3.1 ± 0.13
and 3.26 ± 0.12 for turpentine oil and heat killed bacteria,
confirming the ability of 99mTc-clarithromycin to distinguish
between septic and sterile inflammation [116].
Clindamycin is an antibiotic of lincosamide family, used
for treatment of streptococci and staphylococci infections.
It binds to the 23S rRNA of the 50S ribosomal subunit,
inhibiting the initial stage of the elongation cycle during
protein synthesis [117]. After labelling with 99mTc, in vivo
distribution and scintigraphic imaging were performed,
respectively in rats and rabbits. The infection was induced
using 2 9 108 CFU of S. aureus, while inflammation with
turpentine oil and heat killed bacteria. 99mTc-clindamycin
was eliminated through kidneys and it mostly accumulated
in the infectious foci as compared to inflamed muscles,
indicating a specific binding to living bacteria. However,
the T/NT ratio was not very high, since it was 3.1 ± 0.3
after 1 h post-injection [118].
Others
Mebendazole is an anthelmintic drug with a broad spec-
trum against nematodal and cestodal species; it belongs to
the imidazole group and it is particularly indicated for the
treatment of trichinellosis [119]. In fact, in the study per-
formed by Inceboz et al. [120], the authors wanted to
investigate the biodistribution of 99mTc-mebendazole in a
rat model, infected with T. spiralis, a nematode that is often
present in wild carnivorous animals. Briefly, 750–1000
larvae were orally administrated in rats to induce infectionT
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in the muscles, while healthy rats were used as controls.
Once the infection was established, 99mTc-mebendazole
was given to rats by oral administration or through a tail
vein. Biodistribution data showed a main uptake in the
gastro-intestinal tract, if the administration was oral, while
in kidney if it was injected i.v. The maximum uptake in
muscles was found in the tongue and the diaphragm for
both groups, but also in other infected muscles such as
masseter or semimembranosus muscle, suggesting that
99mTc-mebendazole complex could be a useful imaging
agent to detect T. spiralis infections.
Fluoromaltose is another molecule through which it is
possible to distinguish bacterial infections in vivo from
other pathologies. In this case maltodextrin-based imaging
probes (MDPs) were used, exploiting a bacteria-specific
mechanism of transport, called maltodextrin transporter,
which is absent in mammalian cells. These probes were
internalized only by bacteria with a rapid metabolism with
high sensitivity, detecting low number or bacteria and
discriminating between infection and inflammation [121].
Based on these considerations, Gowrishankar et al. [122]
labelled 6-fluoromaltose with 18F to evaluate its ability to
differentiate bacterial infection from inflammation in a
murine model. Infection was induced with 5 9 107 CFU of
E. coli, while the inflammation was produced with 108
CFU of heat-killed bacteria and turpentine oil. Micro PET/
CT images were acquired as well as biodistribution studies
and histology. A 3D color map from PET/CT images
showed a clear accumulation of 6-[18F]-fluoromaltose in
the infected muscle compared to non infected muscle and a
renal and hepatobiliary excretion, confirmed by biodistri-
bution, histological images and bioluminescence imaging.
Triacetylfusarinine C (TAFC) and ferrioxamine E
(FOXE) are two siderophores, which are produced by
various microorganisms for the binding and storage of iron.
Indeed iron is essential for many metabolic processes of
microorganisms. In biofilms specific transporters for 68Ga-
siderophores are upregulated, resulting in an accumulation
of the radiopharmaceutical in bacteria. Considering the
similar chemistry of iron and gallium, Petrik et al.
[123, 124] investigated the possibility to label TAFC and
FOXE with 68Ga and then they evaluated the capacity of
radiopharmaceuticals to localize infection by A. fumigatus
in a rat model. In vitro studies were also performed and
included a comparison of uptake between different bacteria
(A. fumigatus, P. aeruginosa, S. aureus) and human lung
cancer cells. In vivo studies showed a rapid accumulation
of 68Ga-TAFC and 68Ga-FOXE in A. fumigatus infected
tissues, especially in lungs, while a moderate uptake in the
turpentine oil inflamed muscle and no uptake in S. aureus
infected muscle was observed. These data support the
conclusion that 68Ga-TAFC and 68Ga-FOXE are selective
agents to detect A. fumigatus infection through PET
imaging, with a higher sensitivity for 68Ga-FOXE.
Finally, 2,20-[(8-hydroxyquinolin-7-yl) methy-
lazanediyl] diacetic acid (HQMADA) is an antibacterial
drug, deriving from the reaction between 8-hydrox-
yquinoline and iminodiacetic acid in presence of
paraformaldehyde. It was labelled with 99mTc and, after
in vitro studies such as stability in serum and binding to
bacteria, biodistribution was studied in E. coli mice.
Experimental data revealed a main uptake in liver and
intestine and a high accumulation in the infectious foci
than in sterile inflammation. T/NT ratio was 5.52 ± 0.2
between infected and healthy muscle after 2 h from
injection, while in the inflamed model, both with turpentine
oil and heat-killed E. coli, the T/NT ratios were nearly 2 at
each time point, suggesting that 99mTc-HQMADA complex
can differentiate bacterial infection from sterile inflam-
mation [125].
Summary of systematic analysis of the literature
The systematic analysis was performed by searching in
PubMed, Web of Science, Scopus and Google Scholar
websites, for ‘‘radiolabelled OR radiolabeled OR labelled
OR labeled AND antibiotic* AND bacteria*’’. We
obtained 1193 papers from PubMed of which 25 original
articles were considered, and eight reviews, one case report
and one editorial were excluded. These papers were inte-
grated with similar search in other websites, finally
obtaining 81 original published studies that were analysed
and included in this systematic review and summarized in
Tables 1 and 2. We considered: the type of isotope, the
labelling method, the specific activity of radiopharmaceu-
tical, its stability in serum and/or saline, the animal model
used, the metabolic route, the control experiment and the
obtained results in terms of target muscle/background (T/
NT) ratio, with the purpose of having an objective analysis
as complete as possible.
Ciprofloxacin studies were selected and used as com-
parison to other antibiotics because ciprofloxacin was the
first antibiotic tested in humans. As shown in Table 1,
many groups worldwide obtained conflicting results in
terms of sensibility and specificity. Overall, in animal
models ciprofloxacin showed good sensibility but a lack of
specificity, probably because of labelling issues and poor
stability. In clinical studies data are more complicated to
analyse because different authors used different scoring
systems that may result subjective to interpretation [29], as
it can be seen in Table 1. A multicentre study with
homogeneous criteria of image acquisition and interpreta-
tion is still missing.
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Table 2 shows the results of our analysis of all other
radiolabelled antibiotics. None was studied in man. It is
possible to note that very often different studies are per-
formed by the same group of authors. Overall studies are
published in journals with low impact factor and relevance.
There is low reproducibility and reliability because most
antibiotics were not tested by more than one team. Some-
times reports are incomplete with no in vitro and/or in vivo
data and it was not possible to analyse all experimental
results. It is anyhow remarkable to observe the variability
of labelling procedure, and the high variability of specific
activity of the radiopharmaceutical. Often stability in
serum or saline are not performed or not for enough time.
Animal models are variable and the type of bacteria used
and CFU injected is extremely variable. In particular the
number of bacteria used may be relevant because higher
numbers can give a higher signal by binding more mole-
cules of radiopharmaceutical [7].
Mainly the infection was induced using S. aureus or
E. coli, except when the antibiotic was specific for a certain
bacterium such as A. fumigatus or T. spiralis. The meta-
bolism of most radiopharmaceuticals is renal and rarely
hepatic. The specificity is related to in vivo calculated
target to background ratio (T/NT) using turpentine oil and/
or heat killed bacteria as control. Very rarely we found
in vitro data on binding to bacteria or ex vivo autoradio-
graphy to demonstrate the specificity of binding to bacteria.
Most T/NT ratios were below 4 (poor radiopharmaceuti-
cals), a few were between 4 and 8 (promising radiophar-
maceuticals), and only 99mTc-cefazolin, 99mTc-cefepime,
99mTc-clarithromycin, 99mTc-rufloxacin, 99mTc-ceftriax-
one, 99mTc-levofloxacin, 99mTc-gemifloxacin and 99mTc-
sitafloxacin showed a T/NT ratio higher than 8 (good
radiopharmaceutical). This indicates that most radiola-
belled antibiotics are not candidate for human studies.
Conclusion
From the present systematic review it can deduced how
difficult it is to find a specific imaging agent to detect
bacterial infection and to monitor the effectiveness of
antimicrobial therapy. None of the mentioned radiolabelled
antibiotics is commercially available because of its mini-
mal or very low specific activity or low specificity for
infections versus sterile inflammation or, most frequently
for selective specificity to one kind of bacteria only.
Despite a large number of original papers have been pub-
lished, it is difficult to make a head-to-head comparison
amongst them. Animal models are often different (mice,
rats or rabbits), injected activities and image acquisition
times are different, and, most importantly, the number of
bacteria used for inducing the infection ranges from 105 to
1010, being the main limiting factor for a comparison of
sensitivity.
Another important problem of antibiotics is the risk of
resistance mechanism because bacteria can change very
quickly and drug-resistant strains are often the cause of
recurring infections. Resistance can also be due from a non
specific removal mechanism of antibiotics or sometimes
from an enforced efflux by pumps. Furthermore, bacteria
do not have a high affinity for antibiotics, nor the binding
between the antibiotic and bacteria is specific like the
ligand-receptor interaction in mammalian cells. For these
reasons the gold standard for bacterial infection imaging
has not yet been found. Hopefully in future we will have
many radiopharmaceuticals available, tailored for specific
pathogens, and clinical conditions thus having the maxi-
mum specificity.
It is important also to stress that animal experiments
should always be performed before human studies, with
several different strains and number of bacteria in order to
provide useful information for planning and interpreting
human studies.
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